Optimized Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors


To test a novel technology for delivering high-dose radiation to solid cancers that cannot be removed surgically

Anticipated Impact: 

Safer, more effective treatment of radiation-resistant solid cancers


A key challenge in radiation therapy for cancer is achieving uniform, localized delivery of high doses without exceeding normal tissue tolerance. Dr. Fisher and his team are developing an injectable “radiogel” that provides controlled, high-dose delivery of yttrium-90 (90Y) to solid tumors that cannot be removed surgically. The product consists of a suspension of 90Y-phosphate microspheres in a sterile solution, which is liquid during injection but solidifies at body temperature to capture the microspheres at the injection site and limit radiation exposure to surrounding normal tissues. The radiogel technology could be used to treat a variety of radiation-resistant solid cancers, including those of the liver, brain, head and neck, kidney, and pancreas. LSDF funding will support preclinical testing of radiogel delivery, biodistribution, safety, and therapeutic efficacy as a precursor to clinical trials. Advanced Medical Isotope Corporation (AMIC) is leading commercialization efforts.

Collaborating organization: Advanced Medical Isotope Corporation (AMIC)

Cancer Diagnostics, Therapeutics

Grant Update

Principal Investigator:
Darrell Fisher
Grantee Organization:
Washington State University
Grant Title:
Optimized Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors
Grant Cohort and Year:
2015 Proof of Concept (03)
Grant Period:
03/01/2015 - 02/28/2018 (Completed)
Grant Amount:
Investigators on this proof-of-concept grant have developed and tested a first-of-kind cancer therapeutic agent that offers hope to patients with incurable solid tumors in locations of the body that prevent surgical removal or treatment by other standard or experimental approaches. This new agent was designed to maximize both safety and therapeutic effectiveness. Our commercialization partner, Advanced Medical Isotope Corporation, has filed a de novo new device application with the Food and Drug Administration for approval of this cancer treatment. The FDA subsequently recommended further animal studies to demonstrate both safety and efficacy. We are currently engaged in clinical studies of therapeutic safety and efficacy in a feline (cat) sarcoma model.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
3, 4, 6, 8, 9

Health Impacts

Cancer Diagnostics, Therapeutics